{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:55:57Z","timestamp":1773770157014,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.ejphar.2011.04.016","type":"journal-article","created":{"date-parts":[[2011,4,30]],"date-time":"2011-04-30T18:43:27Z","timestamp":1304189007000},"page":"22-26","source":"Crossref","is-referenced-by-count":4,"title":["Eszopiclone stimulates the hypothalamo-pituitary-adrenal axis in the rat"],"prefix":"10.1016","volume":"661","author":[{"given":"Robert N.","family":"Pechnick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana M.","family":"Lacayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlene M.","family":"Manalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Bholat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Spivak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2011.04.016_bb0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0014-2999(01)00851-2","article-title":"Sedative and anxiolytic effects of eszopiclone's enantiomers and metabolites","volume":"415","author":"Carlson","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00429-008-0192-2","article-title":"Functional role of local GABAergic influences on the HPA axis","volume":"213","author":"Cullinan","year":"2008","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0091-3057(91)90583-N","article-title":"Effects of chlordiazepoxide, flumazenil and DMCM on plasma catecholamine and corticosterone concentrations in rats","volume":"38","author":"De Boer","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2011.04.016_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0022-3956(90)90042-O","article-title":"Neuroendocrine effects of benzodiazepines","volume":"24","author":"De Souza","year":"1990","journal-title":"J. Psychiat. Res."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0025","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0024-3205(87)90029-4","article-title":"Diazepam withdrawal as demonstrated by changes in plasma corticosterone: a role for the hippocampus","volume":"40","author":"Eisenberg","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0030","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/0024-3205(89)90324-X","article-title":"Effects of \u00df-carboline-ethyl-ester on plasma corticosterone\u2014a parallel with antagonist-precipitated diazepam withdrawal","volume":"44","author":"Eisenberg","year":"1989","journal-title":"Life Sci"},{"key":"10.1016\/j.ejphar.2011.04.016_bb0035","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/0028-3908(83)90119-3","article-title":"Actions of benzodiazepines on the neuroendocrine system","volume":"128","author":"Grandison","year":"1983","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2011.04.016_bb0040","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1021\/jm800889m","article-title":"Structural requirements for eszopiclone and zolpidem binding to the \u03b3-aminobutyric acid type-A (GABAA) receptor are different","volume":"51","author":"Hanson","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yfrne.2003.07.001","article-title":"Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenalcortical responsiveness","volume":"24","author":"Herman","year":"2003","journal-title":"Frontiers Neuroendo."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0050","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1124\/jpet.108.146084","article-title":"The modulation of synaptic GABAA receptors in the thalamus by eszopiclone and zolpidem","volume":"328","author":"Jia","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0055","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1210\/jcem-70-5-1462","article-title":"In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications","volume":"70","author":"Kalogeras","year":"1990","journal-title":"J. Clin. Endo. Metab."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0060","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/sleep\/26.7.793","article-title":"Sustained efficacy of eszopiclone over 6months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia","volume":"26","author":"Krystal","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.ejphar.2011.04.016_bb0065","first-page":"595","article-title":"The effects of various doses of minor tranquilizers on plasma corticosteroids in stressed rats","volume":"11","author":"Lahti","year":"1975","journal-title":"Res. Comm. Chem. Path. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0070","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0091-3057(86)90550-2","article-title":"Brain histamine regulation following chronic diazepam treatment and stress","volume":"24","author":"Mazurkiewicz-Kwilecki","year":"1986","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejphar.2005.06.049","article-title":"Effects of benzodiazepines receptor agonists on the hypothalamic-pituitary-adrenocortical axis","volume":"519","author":"Mikkelsen","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0080","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clinthera.2006.04.014","article-title":"Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia","volume":"28","author":"Najib","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0085","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0269881109106927","article-title":"Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics","volume":"24","author":"Nutt","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0090","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0022-3565(25)20232-4","article-title":"The effects of alprazolam and corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal","volume":"258","author":"Owens","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0095","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/0024-3205(88)90367-0","article-title":"Factors modifying the effect of diazepam on plasma corticosterone levels in rats","volume":"43","author":"Pohorecky","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.sleep.2005.06.004","article-title":"An evaluation of the efficacy and safety of eszopiclone over 12months in patients with chronic primary insomnia","volume":"6","author":"Roth","year":"2005","journal-title":"Sleep Med"},{"issue":"suppl 1","key":"10.1016\/j.ejphar.2011.04.016_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00023210-200418001-00004","article-title":"The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents","volume":"18","author":"Sanger","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2011.04.016_bb0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1054-3589(06)54010-4","article-title":"Structure, pharmacology, and function of GABAA receptor subtypes","volume":"54","author":"Sieghart","year":"2006","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00002018-200326040-00004","article-title":"New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon","volume":"26","author":"Terzano","year":"2003","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0120","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0026-895X(25)15030-X","article-title":"Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors","volume":"26","author":"Trifiletti","year":"1984","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0125","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0022-3565(25)20755-8","article-title":"Effects of benzodiazepine agonist exposure on corticotropin-releasing factor content and hormonal stress responses: divergent responses in male and ovariectomized female rats","volume":"278","author":"Wilson","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.04.016_bb0130","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1185\/174234304X15174","article-title":"Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia","volume":"20","author":"Zammit","year":"2004","journal-title":"Curr. Med. Res. Opin."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911004067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911004067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T09:32:19Z","timestamp":1741167139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299911004067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":26,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0014299911004067"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.04.016","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}